Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 331

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 1
Chunk 331
---
 collaborators, business partners, suppliers and customers, while in possession of material inside information. Certain members of our senior management or staff, including persons discharging managerial responsibilities, and their connected persons are subject to additional compliance requirements which are outlined in the code (including but not limited to obtaining written pre-clearance from designated members of management prior to any dealing in any such securities is allowed).

Board Diversity Policy

Our board of directors has established a board diversity policy as our board of directors recognizes the benefits of a board of directors that possesses a balance of skills, experience, expertise, independence and knowledge and diversity of perspectives appropriate to the requirements of our businesses.

We maintain that appointment to our board of directors should be based on merit that complements and expands the skills, experience, expertise, independence and knowledge of the board of directors as a whole, taking into account gender, age, professional experience and qualifications, cultural and educational background, and any other factors that our board of directors might consider relevant and applicable from time to time towards achieving a diverse board of directors. See also” - Directors and Senior Management - Board Diversity.”

Table of Contents

D. Employees.

As of December 31, 2022, 2023 and 2024, we had 2,025, 1,988 and 1,811 full-time employees, respectively. None of our employees are represented by labor unions or covered by collective bargaining agreements. The number of employees by function as of the end of the period for our fiscal years ended December 31, 2022, 2023 and 2024 was as follows:

                                                       2024       2023       2022  
 ───────────────────────────────────────────────────────────────────────────────────
  By Function:                                                                     
  Oncology/Immunology - Research and Development        893        903        958  
  Oncology/Immunology - Commercial                      771        927        880  
  Corporate Head Office and Other                       147        158        187  
  Total                                               1,811      1,988      2,025  

As of December 31, 2024, a total of 108 employees on our Oncology/Immunology research and development team have M. D. or Ph. D. degrees. Additionally, our Other Ventures joint venture Shanghai Hutchison Pharmaceuticals employed a total of 3,007 full time employees as of December 31, 2024, and no such employees are represented by labor unions and